Sp566
CURRENT AND EMERGING THERAPIES FOR ALCOHOL ASSOCIATED LIVER DISEASE
Date
May 7, 2023
Explore related products in the following collection:
Society: AGA
Alcohol associated liver disease is still a very common entity. The session will provide a comprehensive approach to the aforementioned disease including clinical presentations, diagnosis and emerging treatments including liver transplant. LIVE STREAM SESSION
Alcohol associated liver disease is still a very common entity. The session will provide a comprehensive approach to the aforementioned disease including clinical presentations, diagnosis and emerging treatments including liver transplant. LIVE STREAM SESSION
Presenter
Beth Israel Deaconess Medical Center
Tracks
Related Products
PLACEHOLDER
Perturbations in the gut mucosal immune response contributes to IBD. Non-immune cell popopulations including epithelial and stromal cells also play an important role in intestinal inflammation…
AGA Symptom Control and Challenging Issues in Chronic Liver Disease
Symptoms such as intractable pruritus, cramping and fatigue are the most impactful to a patients quality of life and often the most challenging manage. This session provides expert guidance in helping patients with these issues…
MONITORING OF CALPROTECTIN IN INFLAMMATORY BOWEL DISEASE USING A SWEAT BASED WEARABLE DEVICE
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
